Therefore, even for patients who did not experience positive outcomes after receiving prior therapy that contained an anti-EGFR mAb, treatment with MRG003 still showed some antitumor activity in patients with SCCHN and NPC. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.